NCT03558074 - Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

November 29, 2018

Study Completion Date

November 29, 2018

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG

ALK4290

ALK4290 400 mg tablet twice a day

Trial Locations (5)

Jahn Ferenc South-Pest Hospital and Clinic, Budapest

Borsod-Abauj-Zemplen County Hospital and Teaching Hospital, Miskolc

Szabolcs-Szatmar-Bereg County Hospital and University Hospital, Nyíregyháza

University of Szeged Faculty of Medicine, Szeged

Markusovszky University Teaching Hospital, Szombathely